IE00B4Q5ZN47 - Common Stock
NASDAQ:JAZZ (11/28/2022, 12:36:07 PM)+1.32 (+0.86%)
|GICS Sector||Health Care|
|Earnings (Last)||11-09 2022-11-09/amc||Earnings (Next)||N/A N/A|
|Ins Owners||2.92%||Inst Owners||91.2%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 3,200 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).
JAZZ PHARMACEUTICALS PLC
Fifth Fl, Waterloo Exchange, Waterloo Road
DUBLIN DUBLIN D04
CEO: Bruce C. Cozadd
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,...
These stocks are undervalued considering their long-term growth potential.
The next year should be a busy one for this drugmaker.
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.
Innovative products and services could keep these companies growing.
Here you can normally see the latest stock twits on JAZZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.